<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969565</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00060113</org_study_id>
    <secondary_id>ISTCAR511</secondary_id>
    <nct_id>NCT01969565</nct_id>
  </id_info>
  <brief_title>Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma</brief_title>
  <official_title>An Open-label, Single-arm, Phase 1b/ 2 Study of Carfilzomib in Combination With Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Onyx Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of increasing doses of&#xD;
      carfilzomib in combination with dexamethasone&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Logistical reasons&#xD;
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability and Safety of Increasing Doses of Carfilzomib in Combination With Dexamethasone.</measure>
    <time_frame>24 months</time_frame>
    <description>Adverse events will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) adverse event dictionary. The results will be tabulated to examine their frequency, organ systems affected, and relationship to study treatment. The results of laboratory assessments will be evaluated similarly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients With ≥ VGPR (Very Good Partial Response)</measure>
    <time_frame>4 months-8 months</time_frame>
    <description>VGPR will be estimated based on the crude proportion of subjects whose best response is Stringent Complete Response (sCR), Complete Response (CR), and VGPR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR), Defined as sCR, CR, Very Good Partial Response (VGPR), and PR at 4 Cycles</measure>
    <time_frame>4 months</time_frame>
    <description>The ORR will be estimated based on the crude proportion of subjects for whom best overall response is sCR, CR, VGPR, and PR.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Carfilzomib in combination with dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <arm_group_label>Carfilzomib in combination with dexamethasone</arm_group_label>
    <other_name>Kyprolis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Carfilzomib in combination with dexamethasone</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have newly diagnosed multiple myeloma immunoglobulin G (IgG),&#xD;
             immunoglobulin A (IgA), immunoglobulin E (IgE) or immunoglobulin D (IgD) by the&#xD;
             International Myeloma Foundation (IMF) 2003 Diagnostic Criteria&#xD;
&#xD;
          -  Subjects must be treatment naïve.&#xD;
&#xD;
          -  Patient must not have been previously treated with any prior systemic therapy for the&#xD;
             treatment of multiple myeloma.&#xD;
&#xD;
          -  Prior treatment of hypercalcemia or spinal cord compression with corticosteroids does&#xD;
             not disqualify the patient (the dose should not exceed the equivalent of 160 mg of&#xD;
             dexamethasone in a 2 week period).&#xD;
&#xD;
          -  Patients treated with local radiotherapy with or without concomitant exposure to&#xD;
             steroids, for pain control or management of cord/nerve root compression, are eligible.&#xD;
&#xD;
          -  One week must have lapsed since last date of radiotherapy, which is recommended to be&#xD;
             a limited field.&#xD;
&#xD;
          -  Patients who require concurrent radiotherapy should have entry to the protocol&#xD;
             deferred until the radiotherapy is completed and one week have passed since the last&#xD;
             date of therapy.&#xD;
&#xD;
          -  Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of normal medical care, with the understanding that consent may be withdrawn&#xD;
             by the subject at any time without prejudice to future medical care.&#xD;
&#xD;
          -  All necessary baseline studies for determining eligibility must be obtained within 21&#xD;
             days prior to enrollment.&#xD;
&#xD;
          -  Age 18 years at the time of signing Informed Consent.&#xD;
&#xD;
          -  Life expectancy of more than three months.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 or Karnofsky&#xD;
             performance status of ≥ 60.&#xD;
&#xD;
          -  Subject must be able to adhere to the study visit schedule and other protocol&#xD;
             requirements.&#xD;
&#xD;
          -  Written informed consent in accordance with federal, local, and institutional&#xD;
             guidelines.&#xD;
&#xD;
          -  Female subjects of child-bearing potential must have a negative serum pregnancy test&#xD;
             within seven days of the first dose and agree to use dual methods of contraception&#xD;
             during and for 3 months following last dose of drug.&#xD;
&#xD;
          -  Post menopausal females (&gt; 45 years old and without menses for &gt; 1 year) and&#xD;
             surgically sterilized females are exempt from a pregnancy test.&#xD;
&#xD;
          -  Male subjects must use an effective barrier method of contraception during study and&#xD;
             for three months following the last dose if sexually active with a female of&#xD;
             child-bearing potential.&#xD;
&#xD;
          -  Subjects must be able to receive outpatient treatment and laboratory monitoring at the&#xD;
             institute that administers agent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has &gt; Grade 2 peripheral neuropathy on clinical examination within 14 days&#xD;
             before enrollment.&#xD;
&#xD;
          -  Renal insufficiency as measured by calculated creatinine clearance &lt; 15 mL/min by&#xD;
             Cockroft-Gault formula.&#xD;
&#xD;
          -  Subjects with evidence of mucosal or internal bleeding and/or platelet refractory&#xD;
             (i.e., unable to maintain a platelet count 50,000 cells/mm³).&#xD;
&#xD;
          -  Subjects with an absolute neutrophil count (ANC) &lt; 1000 cells/mm³. Growth factors may&#xD;
             not be used to meet ANC eligibility criteria.&#xD;
&#xD;
          -  Total bilirubin &gt; 2.0 mg/dL or bilirubin ≥ 2 x upper limit of normal (ULN).&#xD;
&#xD;
          -  Subjects with a hemoglobin &lt; 8.0 g/dL (Transfusion are permitted).&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) (SGPT) &gt; 2.5 x ULN.&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) ≥ 2.5 x ULN.&#xD;
&#xD;
          -  Major surgery within three weeks of starting study drug (Cycle 1 Day 1).&#xD;
&#xD;
          -  Myocardial infarction within 6 months prior to enrollment or has New York Heart&#xD;
             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe&#xD;
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute&#xD;
             ischemia or active conduction system abnormalities. Prior to study entry, any ECG&#xD;
             abnormality at screening has to be documented by the investigator as not medically&#xD;
             relevant.&#xD;
&#xD;
          -  Clinically relevant active infection requiring either oral or intravenous antibiotics&#xD;
             or antifungal agents.&#xD;
&#xD;
          -  Serious co-morbid medical conditions such as chronic obstructive or chronic&#xD;
             restrictive pulmonary disease, and cirrhosis.&#xD;
&#xD;
          -  Any condition, including laboratory abnormalities, that in the opinion of the&#xD;
             Investigator places the subject at unacceptable risk if he/she were to participate in&#xD;
             the study.&#xD;
&#xD;
          -  Prior malignancy (within the last 3 years) except for adequately treated basal cell or&#xD;
             squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ&#xD;
             prostate cancer or if the expected survival from other malignancy is less than 90% at&#xD;
             5 years.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (Fasting Blood Sugar &gt; 400 despite medical treatment).&#xD;
&#xD;
          -  Known history of POEMS syndrome (plasma cell dyscrasia with polyneuropathy,&#xD;
             organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes).&#xD;
&#xD;
          -  Known HIV infection.&#xD;
&#xD;
          -  Known active hepatitis B or C viral infection.&#xD;
&#xD;
          -  Plasma cell leukemia.&#xD;
&#xD;
          -  Glucocorticoid therapy (prednisone &gt; 20 mg/day or equivalent) within the last three&#xD;
             weeks.&#xD;
&#xD;
          -  Any prior treatment for multiple myeloma with standard regimens or investigative&#xD;
             regimens.&#xD;
&#xD;
          -  Subjects with treatment related myelodysplastic syndrome.&#xD;
&#xD;
          -  Subjects in whom the required program of oral and intravenous fluid hydration is&#xD;
             contraindicated, e.g., due to pre-existing significant pulmonary, cardiac or renal&#xD;
             impairment.&#xD;
&#xD;
          -  Subjects with known primary amyloidosis.&#xD;
&#xD;
          -  Female subject is pregnant or breast-feeding.&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Kaufman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winship Cancer Institute-Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>October 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <results_first_submitted>October 6, 2015</results_first_submitted>
  <results_first_submitted_qc>October 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2015</results_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Jonathan Kaufman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was open to accrual from August 2013 to September 2014.</recruitment_details>
      <pre_assignment_details>One patient consented but withdrew prior to beginning treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Carfilzomib in Combination With Dexamethasone</title>
          <description>Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carfilzomib in Combination With Dexamethasone</title>
          <description>Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tolerability and Safety of Increasing Doses of Carfilzomib in Combination With Dexamethasone.</title>
        <description>Adverse events will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) adverse event dictionary. The results will be tabulated to examine their frequency, organ systems affected, and relationship to study treatment. The results of laboratory assessments will be evaluated similarly.</description>
        <time_frame>24 months</time_frame>
        <population>Patient withdrew consent before receiving treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Carfilzomib in Combination With Dexamethasone</title>
            <description>Carfilzomib will be administered at a dose of 20 mg/m2, with a dose escalation to 36 mg/m2 after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m2, with a dose escalation to 45 mg/m2 after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.&#xD;
Carfilzomib&#xD;
Dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability and Safety of Increasing Doses of Carfilzomib in Combination With Dexamethasone.</title>
          <description>Adverse events will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) adverse event dictionary. The results will be tabulated to examine their frequency, organ systems affected, and relationship to study treatment. The results of laboratory assessments will be evaluated similarly.</description>
          <population>Patient withdrew consent before receiving treatment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patients With ≥ VGPR (Very Good Partial Response)</title>
        <description>VGPR will be estimated based on the crude proportion of subjects whose best response is Stringent Complete Response (sCR), Complete Response (CR), and VGPR.</description>
        <time_frame>4 months-8 months</time_frame>
        <population>Patient withdrew consent before receiving treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Carfilzomib in Combination With Dexamethasone</title>
            <description>Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With ≥ VGPR (Very Good Partial Response)</title>
          <description>VGPR will be estimated based on the crude proportion of subjects whose best response is Stringent Complete Response (sCR), Complete Response (CR), and VGPR.</description>
          <population>Patient withdrew consent before receiving treatment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR), Defined as sCR, CR, Very Good Partial Response (VGPR), and PR at 4 Cycles</title>
        <description>The ORR will be estimated based on the crude proportion of subjects for whom best overall response is sCR, CR, VGPR, and PR.</description>
        <time_frame>4 months</time_frame>
        <population>Patient withdrew consent before receiving treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Carfilzomib in Combination With Dexamethasone</title>
            <description>Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR), Defined as sCR, CR, Very Good Partial Response (VGPR), and PR at 4 Cycles</title>
          <description>The ORR will be estimated based on the crude proportion of subjects for whom best overall response is sCR, CR, VGPR, and PR.</description>
          <population>Patient withdrew consent before receiving treatment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Carfilzomib in Combination With Dexamethasone</title>
          <description>Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One patient consented but withdrew prior to beginning treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jonathan Kaufman, MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1900</phone>
      <email>jlkaufm@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

